Tissue Factor and Tissue Factor Pathway Inhibitor as Key Regulators of Global Hemostasis: Measurement of Their Levels in Coagulation Assays

 

 Buy Article Permissions and Reprints

ABSTRACT

The tissue factor (TF)/factor (F)VIIa complex is the primary initiator of coagulation in vivo. Tissue factor pathway inhibitor (TFPI) is the physiological inhibitor of the TF/FVIIa complex. Deficiencies of either TF or TFPI have not been reported in humans, and a complete absence of either of these two proteins in mice is embryonically lethal. To maintain normal hemostasis, levels of TF and TFPI need to be balanced. Increased levels of TF can overwhelm the inhibitory capacity of TFPI, resulting in thrombosis. Decreased levels of TF are associated with bleeding. Global assays of coagulation are defined as tests capable of evaluating all components of the clotting cascade that are present in plasma. In these tests the thrombogenic surface is either provided by platelets or exogenous phospholipids. Clotting assays currently used in clinical practice are not designed to measure endogenous levels of TF and TFPI. Therefore, there is a need to develop sensitive and specific assays for measuring levels of functional TF and TFPI in whole blood and plasma. These assays could be useful in patient management in many scenarios.

REFERENCES

• 1 Gross P L, Weitz J I. New antithrombotic drugs.  Clin Pharmacol Ther. 2009;  86(2) 139-146
  CrossrefPubMedGoogle Scholar
• 2 Howard E L, Becker K C, Rusconi C P, Becker R C. Factor IXa inhibitors as novel anticoagulants.  Arterioscler Thromb Vasc Biol. 2007;  27(4) 722-727
  CrossrefPubMedGoogle Scholar
• 3 Mackman N, Taubman M. Tissue factor: past, present, and future.  Arterioscler Thromb Vasc Biol. 2009;  29(12) 1986-1988
  CrossrefPubMedGoogle Scholar
• 4 Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis.  Semin Thromb Hemost. 2006;  32(1) 5-10
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Censarek P, Bobbe A, Grandoch M, Schrör K, Weber A A. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant.  Thromb Haemost. 2007;  97(1) 11-14
  PubMedGoogle Scholar
• 6 Bach R R. Tissue factor encryption.  Arterioscler Thromb Vasc Biol. 2006;  26(3) 456-461
  CrossrefPubMedGoogle Scholar
• 7 Maroney S A, Mast A E. Expression of tissue factor pathway inhibitor by endothelial cells and platelets.  Transfus Apheresis Sci. 2008;  38(1) 9-14
  CrossrefPubMedGoogle Scholar
• 8 Hackeng T M, Rosing J. Protein S as cofactor for TFPI.  Arterioscler Thromb Vasc Biol. 2009;  29(12) 2015-2020
  CrossrefPubMedGoogle Scholar
• 9 Heit J A. Cancer and venous thromboembolism: scope of the problem.  Cancer Control. 2005;  12(Suppl 1) 5-10
  PubMedGoogle Scholar
• 10 Kasthuri R S, Taubman M B, Mackman N. Role of tissue factor in cancer.  J Clin Oncol. 2009;  27(29) 4834-4838
  CrossrefPubMedGoogle Scholar
• 11 Tesselaar M E, Romijn F P, Van Der Linden I K, Prins F A, Bertina R M, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?.  J Thromb Haemost. 2007;  5(3) 520-527
  CrossrefPubMedGoogle Scholar
• 12 Khorana A A, Francis C W, Menzies K E et al.. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer.  J Thromb Haemost. 2008;  6(11) 1983-1985
  CrossrefPubMedGoogle Scholar
• 13 Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina R M, Sandset P M. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis.  Blood. 2003;  101(11) 4387-4392
  CrossrefPubMedGoogle Scholar
• 14 Duering C, Kosch A, Langer C, Thedieck S, Nowak-Göttl U. Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke.  Thromb Haemost. 2004;  92(4) 707-712
  PubMedGoogle Scholar
• 15 Ariëns R A, Alberio G, Moia M, Mannucci P M. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.  Thromb Haemost. 1999;  81(2) 203-207
  PubMedGoogle Scholar
• 16 Bladbjerg E M, Madsen J S, Kristensen S R et al.. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study.  J Thromb Haemost. 2003;  1(6) 1208-1214
  CrossrefPubMedGoogle Scholar
• 17 Amini-Nekoo A, Futers T S, Moia M, Mannucci P M, Grant P J, Ariëns R A. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis.  Br J Haematol. 2001;  113(2) 537-543
  CrossrefPubMedGoogle Scholar
• 18 Sidelmann J J, Bladbjerg E M, Gram J, Münster A M, Jespersen J. Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis.  Blood Coagul Fibrinolysis. 2008;  19(5) 405-409
  CrossrefPubMedGoogle Scholar
• 19 Hoke M, Kyrle P A, Minar E et al.. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism.  Thromb Haemost. 2005;  94(4) 787-790
  PubMedGoogle Scholar
• 20 Ollivier V, Wang J, Manly D et al.. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay.  Thromb Res. 2010;  125(1) 90-96
  CrossrefPubMedGoogle Scholar
• 21 Haubold K, Rink M, Spath B et al.. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.  Thromb Haemost. 2009;  101(6) 1147-1155
  PubMedGoogle Scholar
• 22 Santucci R A, Erlich J, Labriola J et al.. Measurement of tissue factor activity in whole blood.  Thromb Haemost. 2000;  83(3) 445-454
  PubMedGoogle Scholar
• 23 Marsik C, Quehenberger P, Mackman N, Osterud B, Luther T, Jilma B. Validation of a novel tissue factor assay in experimental human endotoxemia.  Thromb Res. 2003;  111(4–5) 311-315
  CrossrefPubMedGoogle Scholar
• 24 Zillmann A, Luther T, Müller I et al.. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation.  Biochem Biophys Res Commun. 2001;  281(2) 603-609
  CrossrefPubMedGoogle Scholar
• 25 Koch L, Hofer S, Weigand M A, Frommhold D, Poeschl J. Lipopolysaccharide-induced activation of coagulation in neonatal cord and adult blood monitored by thrombelastography.  Thromb Res. 2009;  124(4) 463-467
  CrossrefPubMedGoogle Scholar
• 26 Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann K G. Immunologic quantitation of tissue factors.  J Thromb Haemost. 2006;  4(8) 1747-1755
  CrossrefPubMedGoogle Scholar
• 27 Luther T, Flössel C, Hietschhold V, Koslowski R, Müller M. Flow cytometric analysis of tissue factor (TF) expression on stimulated monocytes—comparison to procoagulant activity of mononuclear blood cells.  Blut. 1990;  61(6) 375-378
  CrossrefPubMedGoogle Scholar
• 28 Shet A S, Aras O, Gupta K et al.. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes.  Blood. 2003;  102(7) 2678-2683
  CrossrefPubMedGoogle Scholar
• 29 Zwicker J I, Liebman H A, Neuberg D et al.. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.  Clin Cancer Res. 2009;  15(22) 6830-6840
  CrossrefPubMedGoogle Scholar
• 30 Bogdanov V Y, Cimmino G, Tardos J G, Tunstead J R, Badimon J J. Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay.  J Thromb Haemost. 2009;  7(5) 894-897
  CrossrefPubMedGoogle Scholar
• 31 Key N S, Slungaard A, Dandelet L et al.. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease.  Blood. 1998;  91(11) 4216-4223
  PubMedGoogle Scholar
• 32 Aras O, Shet A, Bach R R et al.. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia.  Blood. 2004;  103(12) 4545-4553
  CrossrefPubMedGoogle Scholar

Nigel MackmanPh.D. 

UNC Chapel Hill, 917 Mary Ellen Jones Building

CB7035, Chapel Hill, NC 27599

Email: nmackman@med.unc.edu